Indian drug firm Glenmark Pharmaceuticals Ltd. says GBR 830, a novel investigational drug candidate to treat moderate-to-severe atopic dermatitis, could be a “blockbuster.” The drug is the first biologic that Glenmark has developed in-house and is part of the company’s quest to be more innovation-led and shift from away producing plain-vanilla generics.
The company completed a Phase IIa trial last year of GBR 830 that indicated “clinically meaningful and sustained” improvement in...